Pharmacokinetics of THB001, an orally available, potent and highly selective small molecule inhibitor of wild-type KIT receptor tyrosine kinase, in healthy volunteers
Three Phase I studies in healthy volunteers were conducted to monitor KIT inhibitor depletion in mast cell tissues to determine it’s effectiveness in mast cell driven diseases.